An excellent question! My understanding is that once a drug is approved it can be used off-lable ( not for its officially approved usage.) The problem then could be one of reimbursement by the insurance company. The question you are really asking is could various BP have a deal to have the rights to sell the same drug for different indications. That would be very hard to put together and enforce. The best solution would be for the JV partner to run studies for different indications. The quicker such studies are concluded the higher the revenues from those indications. Hope to hear other views on this excellent question.
I am unsure whether a potential partner would demand rights of exclusivity, but I can pretty much guarantee that if a single partner wanted rights to multiple indications, they'll be paying for each. And they'll be awarding each with discrete milestone payments.
News 
Market Data 
Discover 
